Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alvimopan Extension Study for Opioid-Induced Bowel Dysfunction in Cancer Pain
NCT00135577Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2004
- Primary completion
- Apr 2007
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 2 trial of alvimopan in opioid-induced bowel dysfunction (OIBD), sponsored by Merck & Co.. Started Sep 2004; status: completed.
02
Drugs
alvimopan
03
Conditions
opioid-induced bowel dysfunction (OIBD)
Beyond the preview
Go deeper on NCT00135577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00135577.